Email a Friend
Print ArticleOsteoporosis Health Center
New Test for Osteoporosis Fracture Risk
June 24, 2008 -- An ultrasound exam of the heel combined with an assessment of specific risk factors for bone loss and falling can help predict fracture risk due to osteoporosis, a new study suggests.
Researchers say the combination approach could be used to identify older people with a low fracture risk who may not need X-ray-based bone density tests.
The National Osteoporosis Foundation recommends bone density X-ray testing for all women aged 65 and older and all men aged 70 and older, regardless of their risk factors for bone loss. Testing is also recommended for younger men and women with identified risk factors.
But many people who should have the test are not getting it, researcher Idris Guessous, MD, tells WebMD. "In many areas, lack of access and cost keep people from getting tested, and this is likely to get worse as the population at risk for osteoporosis grows."
By one estimate, the incidence of hip fracture related to bone loss is expected to quadruple by the year 2050. Roughly 10 million Americans -- four out of five of whom are women -- have a diagnosis of osteoporosis; 34 million have low bone mass. Low bone mass puts you at increased risk for developing osteoporosis.
Even if the numbers don't rise as expected, it is clear that the incidence of osteoporosis will outpace the economic resources available to treat the disease, Guessous says. "The development of strategies to better identify [people] that need to be tested is crucial."
Heel Ultrasound Predicts Risk
With this in mind, Guessous and colleagues from Switzerland's Lausanne University Hospital developed their own risk assessment model combining an ultrasound exam of the heel with evaluation of established risk factors for osteoporosis and a simple, office-based test to determine a patient's risk for falling.
They used the model on 6,174 women between the ages of 70 and 85 without a diagnosis of osteoporosis.
All the women were evaluated with a heel-bone quantitative ultrasound (QUS), a test that measures bone density at the heel using sound waves rather than radiation.
Other recorded risk factors for fracture included being over the age of 75, having a history of fracture, having a recent fall, and failing a test in which participants were asked to rise from a chair three times in quick succession without using their arms for balance.
Different versions of the "chair-stand test" are widely used to measure lower body strength and falling risk in frail and elderly populations.
Using this five-item model, the researchers concluded that 1,464 of the women (24%) were at lower risk for fractures and 4,710 (76%) had a higher risk.
The women were then followed for three years, during which time 66 women had a hip fracture. Nine out of 10 fractures occurred among women in the higher-risk group.
The study appears in the July issue of Radiology.
"Fracture risk is not just related to the strength of your bones," says Guessous. "It is also determined by risk of falling, but this risk is often overlooked by clinicians."
He adds that the heel ultrasound combined with risk assessment could prove useful for identifying lower-risk people who may not need further bone density testing.
del.icio.us
VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRPTION ONLY.
INDICATION
Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.
IMPORTANT SAFETY INFORMATION
Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).
Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.
The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.
You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for Vivelle-Dot.
Taking Vitamin D and Calcium Together
Osteoporosis specialist Dr. Ethel Siris on why it's so important to take calcium with Vitamin D.
